Zevra therapeutics announces positive final results from phase 2 clinical trial of kp1077 for idiopathic hypersomnia at sleep 2024 annual meeting

Kp1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog

ZVRA Ratings Summary

ZVRA Quant Ranking